OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
ALINS$0.2257

Intrasense SA

Advanced Medical Equipment & TechnologyVerified

Intrasense operates with a negative equity position of EUR -6.84 million and a cash balance of EUR 797,460, indicating a liquidity risk with a current ratio of 0.87. The enterprise value to revenue ratio of 6.73 suggests a premium valuation relative to its EUR 2.96 million revenue, but the negative EBITDA of EUR -10.68 million results in an EV/EBITDA of -1.87, signaling financial stress. Profitability metrics are mixed: a return on equity of 1.58% is positive but modest, while a return on assets of -1.35% reflects underperformance in asset utilization. Gross profit of EUR 4.44 million is offset by operating and net losses of EUR -10.68 million and EUR -10.81 million, respectively, indicating operational inefficiencies. The company's revenue is concentrated in three divisions: software, peripheral solutions, and services. No geographic breakdown is provided, but the EUR 2.96 million revenue is entirely attributed to disclosed segments. The lack of geographic diversification may increase exposure to regional market risks. Outlook data is not provided, but the EUR 3.305 billion revenue reported in IR observations suggests a significant discrepancy with the EUR 2.96 million in the financial snapshot. This inconsistency raises questions about the accuracy of forward-looking guidance or the comparability of reporting periods. Risk factors include a negative net cash position and a debt-to-equity ratio of -1.36, indicating a high reliance on debt financing. The risk assessment flags liquidity as medium and dilution as low, but the negative equity position suggests potential for future dilution if capital is raised. Recent events include a reported EPS of -EUR 0.07, consistent with the net loss of EUR -10.81 million. No recent filings or transcripts are provided to contextualize operational or strategic changes.

30-day price · ALINS(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyIntrasense SA
TickerALINS.PA
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. Intrasense SA designs and develops 2D and 3D medical imaging software and peripheral solutions for computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scans, generating revenue through software sales, peripheral solutions, and services.

Classification. Intrasense is classified in the Healthcare sector under Advanced Medical Equipment & Technology with 92% confidence, per verified market data.

Intrasense operates with a negative equity position of EUR -6.84 million and a cash balance of EUR 797,460, indicating a liquidity risk with a current ratio of 0.87. The enterprise value to revenue ratio of 6.73 suggests a premium valuation relative to its EUR 2.96 million revenue, but the negative EBITDA of EUR -10.68 million results in an EV/EBITDA of -1.87, signaling financial stress. Profitability metrics are mixed: a return on equity of 1.58% is positive but modest, while a return on assets of -1.35% reflects underperformance in asset utilization. Gross profit of EUR 4.44 million is offset by operating and net losses of EUR -10.68 million and EUR -10.81 million, respectively, indicating operational inefficiencies. The company's revenue is concentrated in three divisions: software, peripheral solutions, and services. No geographic breakdown is provided, but the EUR 2.96 million revenue is entirely attributed to disclosed segments. The lack of geographic diversification may increase exposure to regional market risks. Outlook data is not provided, but the EUR 3.305 billion revenue reported in IR observations suggests a significant discrepancy with the EUR 2.96 million in the financial snapshot. This inconsistency raises questions about the accuracy of forward-looking guidance or the comparability of reporting periods. Risk factors include a negative net cash position and a debt-to-equity ratio of -1.36, indicating a high reliance on debt financing. The risk assessment flags liquidity as medium and dilution as low, but the negative equity position suggests potential for future dilution if capital is raised. Recent events include a reported EPS of -EUR 0.07, consistent with the net loss of EUR -10.81 million. No recent filings or transcripts are provided to contextualize operational or strategic changes.
Key takeaways
  • Intrasense has a negative equity position and operates at a loss, indicating financial distress.
  • The company's EV/EBITDA of -1.87 and EV/Revenue of 6.73 suggest a premium valuation despite poor profitability.
  • Revenue is concentrated in three divisions, with no geographic diversification disclosed.
  • A negative net cash position and high debt-to-equity ratio signal liquidity and solvency risks.
  • Discrepancies between reported revenue figures raise concerns about data consistency and transparency.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyEUR
Revenue$3.0M
Gross profit$4.4M
Operating income-$10.7M
Net income-$10.8M
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets$8.0M
Total liabilities$14.8M
Total equity-$6.8M
Cash & equivalents$797.5k
Long-term debt$9.3M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$0.22
Market cap$11.4M
Enterprise value$19.9M
P/E
Reported non-GAAP P/E
EV/Revenue6.7
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book-$6.8M
Net cash-$8.5M
Current ratio0.9
Debt/Equity-1.4
ROA-1.4%
ROE1.6%
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Advanced Medical Equipment & Technology · cohort 3 companies
MetricALINSActivity
Op margin-360.4%19.4% medp25 17.8% · p75 22.0%bottom quartile
Net margin-364.8%17.7% medp25 16.4% · p75 19.0%bottom quartile
Gross margin150.0%73.5% medp25 71.3% · p75 75.8%top quartile
R&D / revenue6.2% medp25 4.7% · p75 12.0%
CapEx / revenue4.3% medp25 3.9% · p75 4.3%
Debt / equity-136.0%41.5% medp25 29.2% · p75 51.3%bottom quartile
Observations
IR observations
Last actual EPS-0.07 EUR
Last actual revenue3,305,000,000 EUR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 23:18 UTC#061f0acc
Market quoteclose EUR 0.22 · shares 0.05B diluted
no public URL
2026-05-04 23:18 UTC#32c22d69
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 23:19 UTCJob: 1ef55838